Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Acquired Thrombotic Thrombocytopenic Purpura
Clinical Trial
NCT01151423Last updated: 12/5/2025
Cablivi
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
